High KI67 Labeling Index in Resected WHO Grade 1 Meningiomas Correlates With a Higher Rate of Recurrence

2016 ◽  
Vol 96 (2) ◽  
pp. E572
Author(s):  
K. Nowak ◽  
J. Casey ◽  
A. Chitale ◽  
I. Kalchman ◽  
E. Buss ◽  
...  
Keyword(s):  
Labeling Index ◽  
Who Grade ◽  
Ki67 Labeling Index

scholarly journals Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Soonmyung Paik ◽  
Youngmee Kwon ◽  
Moo Hyun Lee ◽  
Ji Ye Kim ◽  
Da Kyung Lee ◽  
...  
Keyword(s):  
Clinical Utility ◽  
Recurrence Score ◽  
Predictive Marker ◽  
Labeling Index ◽  
Systematic Evaluation ◽  
Scoring Methods ◽  
Scoring Method ◽  
Ki67 Labeling Index ◽  
Risk Patients ◽  
Potential Clinical Utility

AbstractAlthough Ki67 labeling index is a potential predictive marker for chemotherapy benefit, its clinical utility has been limited by the lack of a standard scoring method resulting in poor interobserver reproducibility. Especially, there is no consensus on the use of average versus hotspot score for reporting. In order to determine the best method for Ki67 scoring and validate manual scoring method proposed by the International Ki67 Working Group (IKWG), we systematically compared average versus hotspot score in 240 cases with a public domain image analysis program QuPath. We used OncotypeDx Recurrence Score (RS) as a benchmark to compare the potential clinical utility of each scoring methods. Both average and hotspot scores showed statistically significant but only modest correlation with OncotypeDx RS. Only hotspot score could meaningfully distinguish RS low-risk versus high-risk patients. However, hotspot score was less reproducible limiting its clinical utility. In summary, our data demonstrate that utility of the Ki67 labeling index is influenced by the choice of scoring method.

scholarly journals Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma

2018 ◽  
Vol 104 (5) ◽  
pp. 1712-1724 ◽  
Author(s):  
Giada Poli ◽  
Carmen Ruggiero ◽  
Giulia Cantini ◽  
Letizia Canu ◽  
Gianna Baroni ◽  
...  
Keyword(s):  
Disease Free Survival ◽  
Tumor Stage ◽  
Labeling Index ◽  
University Hospital ◽  
Adrenal Tumors ◽  
Adrenocortical Cancer ◽  
Tumor Spread ◽  
Adrenocortical Tumors ◽  
Tumor Invasiveness ◽  
Ki67 Labeling Index

Abstract Context Novel tumor markers are urgently needed to better stratify adrenocortical cancer (ACC) patients and improve therapies for this aggressive neoplasm. Objective To assess the diagnostic and prognostic value of the actin-bundling protein fascin-1 (FSCN1) in adrenocortical tumors. Design, Setting and Participants A local series of 37 malignant/37 benign adrenocortical tumors at Careggi University Hospital and two independent validation ACC cohorts (Cochin, TCGA) from the European Network for the Study of Adrenal Tumors were studied. Main Outcome Measures FSCN1 expression was quantified by immunohistochemistry, Western blot and quantitative RT-PCR in ACC specimens; overall and disease-free survival associated with FSCN1 expression were assessed by Kaplan-Meier analysis and compared with that of Ki67 labeling index and tumor stage. Results Despite the low diagnostic power, in the Florence ACC series, FSCN1 immunohistochemical detection appeared as an independent prognostic factor, also refining results obtained with staging and Ki67 labeling index. The robust prognostic power of FSCN1 levels was further confirmed in two independent ACC cohorts. A positive correlation was found between FSCN1 and steroidogenic factor-1 (SF-1), with a substantially higher expression of both factors in ACCs at advanced stages and with at least one of the three Weiss score parameters associated with invasiveness. Moreover, we demonstrated FSCN1 role in promoting cell invasion in a human ACC cell line only in the case of increased SF-1 dosage. Conclusions These findings show that FSCN1 is a novel independent prognostic marker in ACC and may serve as a potential therapeutic target to block tumor spread.

scholarly journals Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study

2013 ◽  
Vol 104 (11) ◽  
pp. 1539-1543 ◽  
Author(s):  
Yoshiki Mikami ◽  
Takayuki Ueno ◽  
Kenichi Yoshimura ◽  
Hitoshi Tsuda ◽  
Masafumi Kurosumi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Research ◽  
Research Group ◽  
Breast Cancer Research ◽  
Labeling Index ◽  
Ki67 Labeling Index

scholarly journals Multiple Pulmonary Metastases following Total Removal of a Bilateral Parasagittal Meningioma with Complete Occlusion of the Superior Sagittal Sinus: Report of a Case

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Masataka Nakano ◽  
Toshihide Tanaka ◽  
Aya Nakamura ◽  
Mitsuyoshi Watanabe ◽  
Naoki Kato ◽  
...  
Keyword(s):  
Pulmonary Metastases ◽  
Superior Sagittal Sinus ◽  
Labeling Index ◽  
Ki 67 ◽  
Who Grade ◽  
Lung Lesions ◽  
Sagittal Sinus ◽  
Arterial Lumen ◽  
Hypervascular Tumor ◽  
Parasagittal Meningioma

Pulmonary metastases of benign meningiomas are extremely rare. The case of a 34-year-old man with bilateral parasagittal meningioma who developed pulmonary metastases is described. The meningioma was an enormous hypervascular tumor with invasion of the superior sagittal sinus. The tumor was resected completely and histologically diagnosed as transitional meningioma. The Ki-67 labeling index was 5%. Four months after operation, the patient subsequently developed bilateral multiple lung lesions later identified as metastases. The lung lesions were partially removed surgically and histologically diagnosed as meningothelial meningioma WHO grade I. The Ki-67 labeling index was 2%. The histological findings demonstrated that the tumor occupied the arterial lumen and the perivascular space, suggesting that pulmonary tumors might metastasize via the vascular route. The histopathological features and mechanisms of metastasizing meningiomas are reviewed and discussed.

scholarly journals Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens

2020 ◽  
Vol 477 (4) ◽  
pp. 545-555
Author(s):  
Kristina A. Tendl-Schulz ◽  
Fabian Rössler ◽  
Philipp Wimmer ◽  
Ulrike M. Heber ◽  
Martina Mittlböck ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Resection ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Molecular Subtype ◽  
Labeling Index ◽  
Reliable Determination ◽  
Core Needle ◽  
Luminal B ◽  
Ki67 Labeling Index

Abstract Reliable determination of Ki67 labeling index (Ki67-LI) on core needle biopsy (CNB) is essential for determining breast cancer molecular subtype for therapy planning. However, studies on agreement between molecular subtype and Ki67-LI between CNB and surgical resection (SR) specimens are conflicting. The present study analyzed the influence of clinicopathological and sampling-associated factors on agreement. Molecular subtype was determined visually by Ki67-LI in 484 pairs of CNB and SR specimens of invasive estrogen receptor (ER)–positive, human epidermal growth factor (HER2)–negative breast cancer. Luminal B disease was defined by Ki67-LI > 20% in SR. Correlation of molecular subtype agreement with age, menopausal status, CNB method, Breast Imaging Reporting and Data System imaging category, time between biopsies, type of surgery, and pathological tumor parameters was analyzed. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan–Meier method. CNB had a sensitivity of 77.95% and a specificity of 80.97% for identifying luminal B tumors in CNB, compared with the final molecular subtype determination after surgery. The correlation of Ki67-LI between CNB and SR was moderate (ROC-AUC 0.8333). Specificity and sensitivity for CNB to correctly define molecular subtype of tumors according to SR were significantly associated with tumor grade, immunohistochemical progesterone receptor (PR) and p53 expression (p < 0.05). Agreement of molecular subtype did not significantly impact RFS and OS (p = 0.22 for both). The identified factors likely mirror intratumoral heterogeneity that might compromise obtaining a representative CNB. Our results challenge the robustness of a single CNB-driven measurement of Ki67-LI to identify luminal B breast cancer of low (G1) or intermediate (G2) grade.

p53 Expression in Canine Liposarcoma Correlates With Myxoid Variant and Higher Proliferative Activity

2020 ◽  
Vol 57 (5) ◽  
pp. 620-622
Author(s):  
Giancarlo Avallone ◽  
Luisa V. Muscatello ◽  
Alessandro Leoni ◽  
Paola Roccabianca ◽  
Elvio Lepri ◽  
...  
Keyword(s):  
Proliferative Activity ◽  
Mitotic Count ◽  
Labeling Index ◽  
P53 Expression ◽  
Ki67 Labeling Index ◽  
Mdm2 Expression ◽  
Morphological Variants ◽  
Well Differentiated

Canine liposarcoma is classified as well differentiated (WDL), dedifferentiated (DDL), myxoid (ML), and pleomorphic (PL). Overexpression of the protooncogene MDM2 has been reported in WDL and DDL, but little is known regarding the role of p53 in their tumorigenesis. The aim of this study was to assess p53 expression in canine liposarcoma and compare it with subtype, grade, mitotic count (MC), Ki67 labeling index (LI), and MDM2 expression. Forty-seven cases were included (13 WDL, 3 DDL, 7 ML, and 24 PL); 17 were MDM2-positive (13 WDL, 3DDL, and 1ML). Five were p53-positive (4 ML and 1 WDL) but DDL and PL were consistently negative. p53 expression correlated with higher Ki67-LI, higher MC, and myxoid histotype. No correlation was found with grade and MDM2 expression. Based on these results canine liposarcoma seems to embody a group of neoplasms whose subtypes, especially ML, may represent distinct diseases rather than morphological variants of the same entity.

Sign in / Sign up

Export Citation Format

Share Document